Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — Almost no one is prescribing Aduhelm, the controversial new Alzheimer’s treatment that roiled the health care landscape when regulators approved it this summer.

Major health care systems like the Cleveland Clinic made it clear almost immediately that they wouldn’t offer the new therapy, citing a lack of convincing evidence that the drug actually helps treat Alzheimer’s disease. Now, STAT has identified another 15 university-affiliated hospitals that aren’t offering the drug, including Johns Hopkins, University of California Los Angeles, and the University of Michigan.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment